Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

331 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Machine Learning Predicts Oxaliplatin Benefit in Early Colon Cancer.
Chen L, Wang Y, Cai C, Ding Y, Kim RS, Lipchik C, Gavin PG, Yothers G, Allegra CJ, Petrelli NJ, Suga JM, Hopkins JO, Saito NG, Evans T, Jujjavarapu S, Wolmark N, Lucas PC, Paik S, Sun M, Pogue-Geile KL, Lu X. Chen L, et al. Among authors: petrelli nj. J Clin Oncol. 2024 May 1;42(13):1520-1530. doi: 10.1200/JCO.23.01080. Epub 2024 Feb 5. J Clin Oncol. 2024. PMID: 38315963
Clinical Outcome From Oxaliplatin Treatment in Stage II/III Colon Cancer According to Intrinsic Subtypes: Secondary Analysis of NSABP C-07/NRG Oncology Randomized Clinical Trial.
Song N, Pogue-Geile KL, Gavin PG, Yothers G, Kim SR, Johnson NL, Lipchik C, Allegra CJ, Petrelli NJ, O'Connell MJ, Wolmark N, Paik S. Song N, et al. Among authors: petrelli nj. JAMA Oncol. 2016 Sep 1;2(9):1162-9. doi: 10.1001/jamaoncol.2016.2314. JAMA Oncol. 2016. PMID: 27270348 Free PMC article. Clinical Trial.
Initial safety report of NSABP C-08: A randomized phase III study of modified FOLFOX6 with or without bevacizumab for the adjuvant treatment of patients with stage II or III colon cancer.
Allegra CJ, Yothers G, O'Connell MJ, Sharif S, Colangelo LH, Lopa SH, Petrelli NJ, Goldberg RM, Atkins JN, Seay TE, Fehrenbacher L, O'Reilly S, Chu L, Azar CA, Wolmark N. Allegra CJ, et al. Among authors: petrelli nj. J Clin Oncol. 2009 Jul 10;27(20):3385-90. doi: 10.1200/JCO.2009.21.9220. Epub 2009 May 4. J Clin Oncol. 2009. PMID: 19414665 Free PMC article. Clinical Trial.
Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08.
Allegra CJ, Yothers G, O'Connell MJ, Sharif S, Petrelli NJ, Colangelo LH, Atkins JN, Seay TE, Fehrenbacher L, Goldberg RM, O'Reilly S, Chu L, Azar CA, Lopa S, Wolmark N. Allegra CJ, et al. Among authors: petrelli nj. J Clin Oncol. 2011 Jan 1;29(1):11-6. doi: 10.1200/JCO.2010.30.0855. Epub 2010 Oct 12. J Clin Oncol. 2011. PMID: 20940184 Free PMC article. Clinical Trial.
Mutation profiling and microsatellite instability in stage II and III colon cancer: an assessment of their prognostic and oxaliplatin predictive value.
Gavin PG, Colangelo LH, Fumagalli D, Tanaka N, Remillard MY, Yothers G, Kim C, Taniyama Y, Kim SI, Choi HJ, Blackmon NL, Lipchik C, Petrelli NJ, O'Connell MJ, Wolmark N, Paik S, Pogue-Geile KL. Gavin PG, et al. Among authors: petrelli nj. Clin Cancer Res. 2012 Dec 1;18(23):6531-41. doi: 10.1158/1078-0432.CCR-12-0605. Epub 2012 Oct 8. Clin Cancer Res. 2012. PMID: 23045248 Free PMC article.
Capecitabine and oxaliplatin in the preoperative multimodality treatment of rectal cancer: surgical end points from National Surgical Adjuvant Breast and Bowel Project trial R-04.
O'Connell MJ, Colangelo LH, Beart RW, Petrelli NJ, Allegra CJ, Sharif S, Pitot HC, Shields AF, Landry JC, Ryan DP, Parda DS, Mohiuddin M, Arora A, Evans LS, Bahary N, Soori GS, Eakle J, Robertson JM, Moore DF Jr, Mullane MR, Marchello BT, Ward PJ, Wozniak TF, Roh MS, Yothers G, Wolmark N. O'Connell MJ, et al. Among authors: petrelli nj. J Clin Oncol. 2014 Jun 20;32(18):1927-34. doi: 10.1200/JCO.2013.53.7753. Epub 2014 May 5. J Clin Oncol. 2014. PMID: 24799484 Free PMC article. Clinical Trial.
NSABP FC-6: Surgical conversion rate in colorectal cancer patients with unresectable, KRAS wild-type liver metastases receiving mFOLFOX7 plus cetuximab.
Wagman LD, Geller DA, Jacobs SA, Petrelli NJ, Allegra CJ, Lipchik C, Pogue-Geile KL, Srinivasan A, Wang Y, O'Connell MJ; NSABP FC-6 Study Group. Wagman LD, et al. Among authors: petrelli nj. J Surg Oncol. 2022 Dec;126(8):1494-1503. doi: 10.1002/jso.27078. Epub 2022 Sep 16. J Surg Oncol. 2022. PMID: 36111443
331 results